[1. Bergamaschini L, Mannucci P, Federici A, et al. Post-transfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348-55.]Search in Google Scholar
[2. James P, Lillicrap D, Mannucci P. Alloantibodies in von Willebrand disease. Blood 2013; 122: 636-40.10.1182/blood-2012-10-462085373192623297130]Search in Google Scholar
[3. Jokela V, Lassila R, Szanto T, et al. Phenotypic and genotypic characterization of 10 Finnish patients with von Willebrand disease type 3: discovery of two main mutations. Haemophilia 2013; 19, 344-8.10.1111/hae.1222523834637]Search in Google Scholar
[4. Bergamaschini L, Santegelo T, Fariciotti A, et al. Study of complementmediated anaphylaxis in humans. The role of IgG subclasses (IgG1 and/or IgG4) in the complement-activating capacity of immune complexes. J Immunol 1996; 156:1256-61.]Search in Google Scholar
[5. Franchini M, Gandini G, Giuffrida A, et al. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia 2008; 14: 645-6.10.1111/j.1365-2516.2008.01668.x18312363]Open DOISearch in Google Scholar
[6. Mannucci P, Ruggeri Z, Ciavarella N, et al. Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand’s disease: effects on replacement therapy. Blood 1981; 57: 25-31.10.1182/blood.V57.1.25.25]Search in Google Scholar
[7. Pergantou H, Xafaki P, Adamtziki E, et al. The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factor. Haemophilia 2012; 18: e66-7.10.1111/j.1365-2516.2012.02799.x22531022]Open DOISearch in Google Scholar
[8. CSL Behring Canada, Inc. Humate-P® antihemophilic factor / von Willebrand factor complex (human), dried, pasteurized. Product monograph. 2014. Available from: http://www.cslbehring.ca/docs/995/828/2014-03-11_170453_E_Humate-P_PM_Approved.pdf (accessed 22 April 2016).]Search in Google Scholar
